US5919908A - Protein formulation comprising coagulation factor VIII or factor IX in an aqueous solution - Google Patents

Protein formulation comprising coagulation factor VIII or factor IX in an aqueous solution Download PDF

Info

Publication number
US5919908A
US5919908A US08/913,263 US91326397A US5919908A US 5919908 A US5919908 A US 5919908A US 91326397 A US91326397 A US 91326397A US 5919908 A US5919908 A US 5919908A
Authority
US
United States
Prior art keywords
aqueous solution
drug product
final drug
factor viii
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08/913,263
Other languages
English (en)
Inventor
Thomas Osterberg
Angelica Fatouros
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Original Assignee
Pharmacia and Upjohn AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn AB filed Critical Pharmacia and Upjohn AB
Assigned to PHARMACIA & UPJOHN AB reassignment PHARMACIA & UPJOHN AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FATOUROS, ANGELICA, OSTERBERG, THOMAS
Application granted granted Critical
Publication of US5919908A publication Critical patent/US5919908A/en
Assigned to BIOVITRUM AB reassignment BIOVITRUM AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PHARMACIA AB
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Definitions

  • the present invention relates to a final drug product of a plasma protein selected from the group consisting of coagulation factor VIII and factor IX, in an aqueous solution, wherein the concentration of oxygen in the solution is reduced and/or the solution contains an antioxidant, and wherein the solution further contains a carbohydrate in a concentration of at least 350 mg/ml.
  • a plasma protein selected from the group consisting of coagulation factor VIII and factor IX
  • the concentration of oxygen in the solution is reduced and/or the solution contains an antioxidant
  • the solution further contains a carbohydrate in a concentration of at least 350 mg/ml.
  • the present invention also relates to a process for preparing the final drug product, and a method for improving the long-term stability of coagulation factor VIII and factor IX in an aqueous solution, wherein the solution contains a carbohydrate in a concentration of at least 350 mg/ml, and wherein the solution is stored in its final container under an oxygen-reduced atmosphere.
  • the stability of proteins is generally a problem in pharmaceutical industry. It has often been solved by drying the protein in various drying processes, such as freeze-drying. The protein has thereafter been distributed and stored in dried form. The solution before drying or freeze-drying, the dried material and the re-constituted product should all be stable, to avoid a substantial loss of activity in the drying process, as well as during storage or handling.
  • the freeze-drying process is a costly and time consuming process step, which reduces the yield of the product. It would therefore be a great advantage if this step could be avoided when preparing a commercial product.
  • the patient necessarily has to reconstitute the dried protein in a solvent before use, which could be inconvenient for the patient.
  • Hemophilia is an inherited disease which has been known for centuries but it is only within the last four decades that it has been possible to differentiate between the various forms; hemophilia A and hemophilia B. Hemophilia A is the most frequent form. It affects only males with an incidence of one or two individuals per 10,000 live-born males. The disease is caused by strongly decreased level or absence of biologically active coagulation factor VIII (antihemophilic factor), which is a protein normally present in plasma.
  • the clinical manifestation of hemophilia A is a strong bleeding tendency and before treatment with factor VIII concentrates was introduced, the mean age of the patients concerned was less than 20 years. Concentrates of factor VIII obtained from plasma have been available for about three decades. This has improved the situation for treatment of hemophilia patients considerably and offered them possibility of living a normal life.
  • HSA human serum albumin
  • WO-A-94/26286 to Pharmacia proposes reducing the oxygen concentration as a means to improve the stability of factor VIII solutions ready for use.
  • carbohydrates such as disaccharides or sugar alcohols, have been used previously for stabilizing solutions containing conventional factor VIII products with a low purity.
  • patent specification WO-A-91/10439 to Octapharma discloses injectable solutions containing factor VIII or factor IX, comprising natural or synthetic disaccharides in a concentration of from 0.1 up to 0.9 mol/l.
  • Carbohydrates such as disaccharides or sugar alcohols, have been used previously also for stabilizing factor VIII compositions during heat treatment for inactivating viruses.
  • patent specification EP-B-0 117 064 to Green Cross discloses the presence of at least 1,500 mg/ml of a sugar alcohol or a disaccharide stabilizer, preferably sorbitol or saccharose. The process can be carried out for 3 up to 24 hours at 30 to 80° C., or for 1 min at 90° C.
  • the sugar alcohol or disaccharide are removed after the heat treatment, e.g. by ultrafiltration.
  • Patent specification EP-A-0 018 561 to Behringwerke discloses the presence of an amino acid and 20 to 60% (w/w) of a monosaccharide, an oligosaccharide or a sugar alcohol. This corresponds to 500 to 1,500 mg/ml of saccharide or alcohol assuming the specific gravity of the solution to be 1. The process can be carried out for 1 min up to 48 hours, at 30 to 100° C.
  • Patent specification WO-A-94/17834 to Octapharma discloses heat treating compositions containing a protein and a dialkylphosphate or trialkylphosphate for 5 up to 30 hours at 55 up to 67° C. to inactivate viruses devoid of lipid envelopes.
  • the composition can further contain stabilizing agents, such as saccharose, sorbitol or short-chained neutral amino acids.
  • WO-A-87/00196 to Quadrant Bioresources discloses the use of trehalose for protecting proteins and other macromolecules from denaturation during drying at ambient temperature.
  • the examples reveal that the compounds tested, mainly antibodies and enzymes, are not only stabilized during the drying procedure, but are also stabilized against long-term storage at relatively high ambient temperature.
  • WO-A-91/18091 to Quadrant Holdings Cambridge it is stated that sugars in general are of limited use for stabilizing biological substances or organic compounds. Specifically, it is stated that non-reducing sugars, such as sucrose, provide very inferior long-term stabilization. To overcome this problem, WO-A-91/18091 discloses the use of certain sugar or sugar derivatives which can be dried without crystallizing and are non-reducing polyhydroxy compounds capable of replicating the effect of trehalose.
  • the sugar or sugar derivatives are selected from (i) a non-reducing glycoside of a polyhydroxy compound selected from sugar alcohols and other straight chain polyalcohols, or (i) a non-reducing oligosaccharide selected from raffinose, stachyose and melezitose.
  • a non-reducing glycoside of a polyhydroxy compound selected from sugar alcohols and other straight chain polyalcohols or (i) a non-reducing oligosaccharide selected from raffinose, stachyose and melezitose.
  • the protein could be formulated and distributed to the patient as a stable solution without the addition of albumin and with a prolonged storage life. Also for the patient such a solution would facilitate the handling of the final drug product. The patient could thus administer, e.g. inject, the content of the final drug product directly without reconstitution.
  • Factor VIII solutions are thus virus inactivated by heat treating the solutions containing various stabilizers for a period of time which is less than about two days.
  • Techniques to stabilize proteins subjected to a high temperature for a short period of time cannot, however, be directly transferred to stability in storage at a low or ambient temperature for several months or years. This is especially true since, in general, the saccharides or sugar alcohols added are removed, intentionally or inevitably, in the process steps following the heat treatment.
  • Schwinn et al Arzneim.-Forsch/Drug Res., Vol. 39 (II), 10, p. 1302-1305 (1989). Also, the feasibility of the formulation in sterile manufacturing must be considered.
  • aqueous factor VIII solutions containing a high proportion of carbohydrates can be sterile filtered directly without an intermediate step to lower the concentration of the carbohydrates.
  • the present invention relates to a final drug product of a plasma protein selected from the group consisting of coagulation factor VIII and factor IX, in an aqueous solution, wherein the concentration of oxygen in the solution is reduced and/or the solution contains an antioxidant, and wherein the solution further contains a carbohydrate in a concentration of at least 350 mg/ml, for essentially retaining the protein activity after storage for at least 6 months.
  • the protein activity is retained to a higher degree when the concentration of the carbohydrate lies in the range of from 450 mg/ml up to saturation at the conditions prevailing in the final drug product.
  • the concentration of the carbohydrate lies in the range of from 550 mg/ml up to saturation at the conditions prevailing in the final drug product.
  • the concentration of the carbohydrate lies in the range of from 650 mg/ml up to saturation at the conditions prevailing in the final drug product.
  • the saturation concentration for each carbohydrate is e.g. influenced by the temperature, ionic strength, pH, and other excipients if present.
  • the final drug product of the present invention is stored for at least 6 months with essentially retained protein activity.
  • essentially retained activity relates to an activity in the range of from 70 up to 130% of the initial value, preferably in the range of from 80 up to 120% of the initial value. The latter range is consistent with the requirements of the test for potency for Freezedried Human Coagulation Factor VIII.
  • the activity must be retained within the range of from 80 up to 120% of the labeled value.
  • the present final drug products are stored for at least 12 months, and preferably for at least 18 months, with essentially retained factor VIII activity. More preferably, the present final drug products are stored for at least 24 months.
  • the present final drug product can be stored at a temperature in the range of from 0 up to 40° C.
  • the present final drug product is suitably stored at a temperature in the range of from 2 up to 30° C., and preferably at a temperature in the range of from 4 up to 20° C. It is even quite possible to store the present final drug product during a long-term period at a temperature in the range of from 10 up to 25° C.
  • Final drug product relates to a stable, generally injectable aqueous solution in its final container.
  • the final drug product thus comprises a stable aqueous solution ready for use.
  • the final drug product is obtained after purification including one or more sterile filtering steps, and, optionally, one or more virus-inactivation steps.
  • Suitable containers in the present invention are e.g. vials, syringes and injection devices.
  • the carbohydrate of the present invention can be selected from any pharmaceutically acceptable natural or synthetic carbohydrate, such as a monosaccharide, disaccharide, oligosaccharide, polysaccharide or sugar alcohol or mixtures thereof.
  • a monosaccharide such as sucrose (saccharose), trehalose, maltose, cellobiose and lactose.
  • polysaccharides are starch and derivatives thereof, and cellulose and derivatives thereof.
  • Sugar alcohols contain hydroxy groups, and are obtained by reduction of various monosaccharides. For example, sorbitol is obtained by reduction of glucose, and mannitol is obtained from mannose.
  • the carbohydrate of the present invention is suitably selected from the group consisting of natural or synthetic disaccharides, and sugar alcohols, and mixtures thereof. More suitably, the carbohydrate is non-reducing, since this reduces the risk for degradation of the coagulation factor VIII and factor IX molecules.
  • non-reducing carbohydrates are sucrose, trehalose, mannitol, sorbitol, galactitol and xylitol.
  • the non-reducing carbohydrate is sucrose or sorbitol, or mixtures thereof. More preferably, the carbohydrate is sucrose.
  • the invention also relates to a process for preparing the final drug product, wherein the plasma protein is mixed with an aqueous solution, or wherein the plasma protein is eluted from the last purifying step with an aqueous buffer solution. Thereafter, a carbohydrate is added to the obtained aqueous solution containing the plasma protein. The carbohydrate is added such that the concentration of carbohydrate is at least 350 mg/ml in the final drug product.
  • the concentration of carbohydrate of the aqueous solution containing the plasma protein lies in the range of from 450 mg/ml up to saturation at the conditions prevailing in the final drug product, preferably in the range of from 550 mg/ml up to saturation, and more preferably in the range of from 650 mg/ml up to saturation.
  • the aqueous solution containing the plasma protein and a carbohydrate is then sterile filtered. Thereafter, the sterile plasma protein solution containing carbohydrate is dispensed in its final container whereupon the oxygen concentration of the plasma protein solution is reduced.
  • the two steps following the sterile filtration may also be carried out in the reverse order, i.e. the oxygen concentration of the sterile plasma protein solution containing carbohydrate is first reduced whereupon the plasma protein solution is dispensed in its final container.
  • the concentration of oxygen is reduced either by subjecting the aqueous solution to an inert gas atmosphere, by reducing the pressure, or by first reducing the pressure and thereafter introducing an inert gas.
  • the latter process is preferably repeated in several cycles.
  • the oxygen concentration in the solution will be substantially lower than would be the case if the surrounding atmosphere consisted of air.
  • the oxygen concentration in the solution can be reduced to a low level, without a substantial loss in plasma protein activity.
  • the oxygen content in the solution can be below 200 ppm, suitably below 50 ppm, preferably below 10 ppm and more preferably below 2 ppm.
  • the oxygen content in the container used can be reduced and maintained at a low level in the same way, preferably by subjecting the container to an inert gas atmosphere.
  • the aqueous solution containing a plasma protein and a carbohydrate is suitably stored under an inert gas such as nitrogen, argon or helium, to essentially maintain the low content of oxygen.
  • the inert gas is preferably a non-noble inert gas, and more preferably nitrogen.
  • the low content of oxygen can also be essentially maintained by adding an antioxidant to the aqueous solution.
  • an antioxidant is added before the sterile filtering step and the concentration of oxygen is reduced either by subjecting the aqueous solution to an inert gas atmosphere, by reducing the pressure, or by first reducing the pressure and thereafter introducing an inert gas, preferably repeated in several cycles.
  • an antioxidant is added to the aqueous solution before the sterile filtering step, without reducing the oxygen concentration by other means.
  • the antioxidant can be selected from glutathione, acetylcysteine, methionine, tocopherol, butyl hydroxy toluene, butyl hydroxy anisole or phenolic compounds.
  • the antioxidant is at least one compound selected from the group consisting of glutathione, acetylcysteine and methionine.
  • the concentration and total amount of the antioxidant depends on the compound used. Therefore, no concentration or amount can generally be given. It is, however, important that the total amount of antioxidant, if used, is a pharmaceutically acceptable amount.
  • Complexing agents such as EDTA and citric acid, can also be present in small concentrations for stabilizing the formulation, if they exhibit a stronger affinity for destabilizing metal ions than for the metal ions associating the chains of e.g. factor VIII.
  • the invention also relates to a method for improving the long-term stability of plasma proteins in an aqueous solution, wherein the solution further contains a carbohydrate in a concentration of at least 350 mg/ml, and that the solution is stored in its final container under an oxygen-reduced atmosphere, preferably under an inert gas atmosphere.
  • the plasma protein is factor VIII and the concentration of carbohydrate of the aqueous solution stored in its final container lies in the range of from 450 mg/ml up to saturation at the conditions prevailing in the final drug product, preferably in the range of from 550 mg/ml up to saturation, and more preferably in the range of from 650 mg/ml up to saturation.
  • the pH of the solution is suitably in the range of from 6.0 up to 8.0, preferably from 6.5 up to 7.5.
  • a non-ionic surfactant is preferably present in the solution.
  • the non-ionic surfactant if present, is preferably chosen from block co-polymers such as a poloxamer or polyoxyethylene sorbitan fatty acid ester, such as polysorbate 20 or polysorbate 80.
  • the non-ionic surfactant should, if present, be used in a concentration above the critical micelle concentration (CMC). See Wan and Lee, Journal of Pharm Sci, 63, p. 136-137, 1974.
  • CMC critical micelle concentration
  • the polyoxyethylene sorbitan fatty acid ester is thus preferably used in a concentration of at least 0.01 mg/ml.
  • the aqueous solution can further contain sodium or potassium chloride, suitably in a concentration of more than 0.1M, preferably more than 0.25M.
  • the aqueous solution suitably contains a buffering agent, in a concentration of more than 1 mM, preferably 10 to 95 mM.
  • the buffering agent is preferably an amino acid selected from the group consisting of L-histidine, lysine and arginine, or mixtures thereof. More preferably, the buffering agent is L-histidine.
  • the final drug product preferably comprises an aqueous solution containing
  • sodium chloride suitably in a concentration of more than 0.1M, and preferably more than 0.25M
  • calcium salt such as calcium chloride or calcium gluconate, preferably in a concentration of more than 0.5 mM.
  • a buffering agent such as L-histidine, in a concentration of more than 1 mM
  • a disaccharide or a sugar alcohol preferably sucrose or sorbitol, in a concentration of at least 350 mg/ml.
  • Factor VIII concentrates derived from human plasma contain several fragmented fully active factor VIII forms as described by Andersson et al, Proc. Natl. Acad. Sci. USA, 83, p. 2979-83 (May 1986).
  • the smallest active form has a molecular mass of 170 kDa and consists of two chains of 90 kDa and 80 kDa held together by a metal ion bridge.
  • r-VIII SQ The truncated recombinant factor VIII molecule is termed r-VIII SQ and is produced by Chinese Hamster Ovary (CHO) cells in a cell culture process in serum-free medium.
  • the specific activity of r-VIII SQ is about 15,000 IU VIII:C per mg of total protein.
  • the structure and biochemistry of r-VIII SQ have been described in WO-A-91/09122 assigned to Pharmacia AB.
  • factor VIII can be either plasma factor VIII or recombinant factor VIII.
  • factor VIII when factor VIII is recombinant it can be full-length factor VIII, or preferably, a deletion derivative of full-ength factor VIII. More preferably, the deletion derivative is recombinant factor VIII SQ (r-VIII SQ).
  • a deletion derivative is defined as a coagulation factor VIII, in which the whole or a part of the ⁇ -domain is missing.
  • the association of the heavy and light chains of factor VIII, is dependent on the presence of calcium (or other divalent metal ions).
  • calcium was added as calcium chloride (CaCl 2 ), but other salts such as calcium gluconate, calcium glubionate or calcium gluceptate can also be used, preferably in a concentration of more than 0.5 mM.
  • the present invention can be used advantageously for a wide variety of factor VIII products.
  • the present invention can be used to further stabilize plasma factor VIII which is already stabilized by association with its carrier protein, the von Willebrand factor (vWf).
  • vWf the von Willebrand factor
  • the advantage of the present invention becomes, however, more pronounced with highly purified factor VIII products, since these products are more unstable than less purified products containing e.g. the vWf.
  • factor VIII products containing small amounts of the vWf or no vWf at all are much more liable to degradation. Therefore, the present invention is suitably used with factor VIII products exhibiting a ratio of factor VIII:C (IU) to vWf:Ag (IU) of at least 2:1, more suitably of at least 10:1 and preferably of at least 100:1. More preferably, the factor VIII product of the present invention contains no vWf.
  • the specific factor VIII activity in the final drug product of the present invention is suitably at least 1,000 IU/mg of total protein, and more suitably at least 3,000 IU/mg of total protein.
  • the specific factor VIII activity in the final drug product of the present invention is preferably at least 5,000 IU/mg of total protein, and more preferably at least 10,000 IU/mg of total protein.
  • the factor VIII activity in the final drug product can be in the range of from 10 up to 50,000 IU/ml, suitably from 50 up to 25,000 IU/ml, and preferably from 100 up to 10,000 IU/ml.
  • the present invention is advantageously used for final drug products of factor VIII and factor IX which have been stabilized without addition of albumin.
  • the clarified conditioned medium was pH adjusted and applied to a S-Sepharose FF column. After washing, factor VIII was eluted with a salt buffer containing 5 mM CaCl 2 .
  • Immunoadsorption was carried out on an immunoaffinity resin where the ligand was a monoclonal antibody (8A4) directed towards the heavy chain of Factor VIII.
  • the S-eluate was treated with 0.3% TNBP and 1% Octoxynol 9.
  • the column was equilibrated, washed and factor VIII was eluted with a buffer containing 0.05M CaCl 2 and 50% ethylene glycol.
  • the mAb-eluate was loaded on a Q-Sepharose FF column, equilibrated with the elution buffer in the immunoaffinity step. After washing, factor VIII was eluted with 0.05M L-histidine, 4 mM CaCl 2 , 0.6M NaCl, pH 6.8.
  • the Q-eluate was applied to a gel filtration column (Superdex 200 p.g.). Equilibration and elution was carried out with a formulation buffer containing L-Histidine, sodium chloride, calcium chloride and polysorbate 80 (see example 1 below), giving the composition according to the examples below.
  • coagulation factor VIII Factor VIII:C
  • Factor Xa Activated factor X
  • S-2222 synthetic chromogenic substrate
  • I-2581 a thrombin inhibitor
  • the reaction is stopped with acid, and the VIII:C, which is proportional to the release of pNA (para-nitroaniline), is determined photometrically at 450 nm against a reagent blank.
  • the unit of factor VIII:C is expressed in international units (IU) as defined by the current International Concentrate Standard (IS) established by WHO.
  • the relative standard deviation (RSD) of the method is 7%.
  • Recombinant factor VIII (r-VIII SQ) was prepared according to the method described under Experimental.
  • the factor VIII used in the Examples is highly purified, i.e. has a specific activity of more than 5,000 IU/mg of total protein, and is stabilized without the addition of albumin.
  • the dispensed volume in the vials was 1 ml, the headspace contained nitrogen and the pH was about 7.
  • Recombinant factor VIII (r-VIII SQ) was prepared according to the method described under Experimental.
  • the factor VIII used in the Examples is highly purified, i.e. has a specific activity of more than 5,000 IU/mg of total protein, and is stabilized without the addition of albumin.
  • the dispensed volume in the vials was 1 ml.
  • the stabilizers used in the storage tests of Example 2 were of Ph. Eur. quality.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
US08/913,263 1995-03-31 1996-03-09 Protein formulation comprising coagulation factor VIII or factor IX in an aqueous solution Expired - Lifetime US5919908A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9501189 1995-03-31
SE9501189A SE9501189D0 (sv) 1995-03-31 1995-03-31 Protein formulation
PCT/SE1996/000419 WO1996030041A1 (en) 1995-03-31 1996-03-29 Protein formulation comprising coagulation factor viii or factor ix in an aqueous solution

Publications (1)

Publication Number Publication Date
US5919908A true US5919908A (en) 1999-07-06

Family

ID=20397788

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/913,263 Expired - Lifetime US5919908A (en) 1995-03-31 1996-03-09 Protein formulation comprising coagulation factor VIII or factor IX in an aqueous solution

Country Status (14)

Country Link
US (1) US5919908A (de)
EP (1) EP0819010B1 (de)
JP (1) JP3953102B2 (de)
AT (1) ATE251467T1 (de)
AU (1) AU709642B2 (de)
BR (1) BR9607922A (de)
CA (1) CA2216098C (de)
DE (1) DE69630291T2 (de)
DK (1) DK0819010T3 (de)
ES (1) ES2208736T3 (de)
NZ (1) NZ305028A (de)
PT (1) PT819010E (de)
SE (1) SE9501189D0 (de)
WO (1) WO1996030041A1 (de)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586573B1 (en) * 1999-02-22 2003-07-01 Baxter International Inc. Albumin-free Factor VIII formulations
US20040127537A1 (en) * 2002-06-26 2004-07-01 Gokarn Yatin R. Stable liquid parenteral parecoxib formulation
ES2229931A1 (es) * 2003-10-03 2005-04-16 Probitas Pharma, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
US20060159656A1 (en) * 1999-07-15 2006-07-20 American Home Products Corp. Formulations for IL-11
US20070105782A1 (en) * 2005-10-07 2007-05-10 Board Of Trustees Of Southern Illinois University Protectant Combinations for Reducing Toxicities
US20080069245A1 (en) * 2001-11-29 2008-03-20 Matsushita Electric Industrial Co., Ltd. Coding distortion removal method, video encoding method, video decoding method, and apparatus and program for the same
US20100168018A1 (en) * 2008-11-07 2010-07-01 Baxter International Inc. Factor viii formulations
US20100316625A1 (en) * 2007-12-21 2010-12-16 Inspiration Biopharmaceuticals, Inc. Stabilized factor ix formulations containing trehalose
AU2010291009B2 (en) * 2009-09-04 2013-09-26 Arecor Limited Stable formulation of Factor VIII

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
DE10261126A1 (de) 2002-08-13 2004-03-04 Aventis Behring Gmbh Lagerungsstabile, flüssige Fibrinogen-Formulierung
DE602004019761D1 (de) * 2003-01-08 2009-04-16 Novartis Vaccines & Diagnostic Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
CN1767815A (zh) * 2003-03-31 2006-05-03 阿尔萨公司 非水单相载体和使用这类载体的制剂
EP2113564A1 (de) 2008-05-01 2009-11-04 Arecor Limited Proteinformulierung
MX2011001624A (es) 2008-08-21 2011-03-28 Octapharma Ag Factor viii y ix humano producido en forma recombinante.
GB0915481D0 (en) * 2009-09-04 2009-10-07 Arecor Ltd Stable manufacture of factor V111
EP2538967A1 (de) * 2010-02-24 2013-01-02 Arecor Limited Stabile zusammensetzungen für faktor ix
EP2361636A1 (de) 2010-02-26 2011-08-31 CSL Behring AG Immunglobulinpräparat und Aufbewahrungssystem für ein Immunglobulinpräparat
JP2019043961A (ja) * 2010-04-20 2019-03-22 オクタファルマ・アーゲー 医薬タンパク質の新規な安定化剤
CA2796729C (en) * 2010-04-20 2020-06-23 Octapharma Ag Melezitose for stabilizing human blood plasma proteins
CN106687126B (zh) 2014-08-04 2020-07-28 杰特有限公司 因子viii制剂
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
JP2025512143A (ja) 2020-11-09 2025-04-17 武田薬品工業株式会社 酸化ケイ素吸着を使用する血漿からのｆｖｉｉｉの精製

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4297344A (en) * 1979-04-25 1981-10-27 Behringwerke Aktiengesellschaft Blood coagulation factors and process for their manufacture
US4447416A (en) * 1982-04-28 1984-05-08 American National Red Cross Plasma protein concentrates of reduced thrombogenicity and their use in clinical replacement therapy
EP0117064A2 (de) * 1983-01-20 1984-08-29 Green Cross Corporation Verfahren zur Hitzebehandlung vom Blutgerinnungsfaktor VIII
EP0197901A1 (de) * 1985-03-05 1986-10-15 Pharmacia AB (reg.number 556131-9608) Biologisch aktive Fragmente von humanem Antihämophiliefaktor, Methode zu ihrer Herstellung und pharmazeutische Präparate
US4891319A (en) * 1985-07-09 1990-01-02 Quadrant Bioresources Limited Protection of proteins and the like
WO1991009122A1 (en) * 1989-12-15 1991-06-27 Kabivitrum Ab A recombinant human factor viii derivative
WO1991018091A1 (en) * 1990-05-14 1991-11-28 Quadrant Holdings Cambridge Limited Stabilization of biological macromolecular substances and other organic compounds
EP0556096A1 (de) * 1992-02-13 1993-08-18 Association Pour L'essor De La Transfusion Sanguine Dans La Region Du Nord Zusammensetzung zur Stabilisierung von Blutplasma im Laufe der Pasteurisation und pasteurisierte Plasmalösung für therapeutische Verwendung
EP0556609A1 (de) * 1992-02-20 1993-08-25 EUKA BAUELEMENTE VERKAUFSGESELLSCHAFT mbH Bahnsteig
US5328694A (en) * 1990-01-19 1994-07-12 Octapharma Ag Stable injectable solution of factor VIII
WO1994017834A1 (de) * 1993-02-09 1994-08-18 Octapharma Ag Verfahren zur inaktivierung von viren, die nicht mit lipidhüllen versehen sind
WO1994026286A1 (en) * 1993-05-07 1994-11-24 Pharmacia Ab Oxygen-reduced aqueous solution of factor viii
WO1995007713A1 (en) * 1993-09-13 1995-03-23 Baxter International Inc. Activated factor viii as a therapeutic agent and method of treating factor viii deficiency
US5733873A (en) * 1992-10-02 1998-03-31 Pharmacia & Upjohn Ab Composition comprising coagulation factor VIII formulation, process for its preparation and use of a surfactant as stabilizer

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4297344A (en) * 1979-04-25 1981-10-27 Behringwerke Aktiengesellschaft Blood coagulation factors and process for their manufacture
US4447416A (en) * 1982-04-28 1984-05-08 American National Red Cross Plasma protein concentrates of reduced thrombogenicity and their use in clinical replacement therapy
EP0117064A2 (de) * 1983-01-20 1984-08-29 Green Cross Corporation Verfahren zur Hitzebehandlung vom Blutgerinnungsfaktor VIII
EP0197901A1 (de) * 1985-03-05 1986-10-15 Pharmacia AB (reg.number 556131-9608) Biologisch aktive Fragmente von humanem Antihämophiliefaktor, Methode zu ihrer Herstellung und pharmazeutische Präparate
US4891319A (en) * 1985-07-09 1990-01-02 Quadrant Bioresources Limited Protection of proteins and the like
WO1991009122A1 (en) * 1989-12-15 1991-06-27 Kabivitrum Ab A recombinant human factor viii derivative
US5328694A (en) * 1990-01-19 1994-07-12 Octapharma Ag Stable injectable solution of factor VIII
WO1991018091A1 (en) * 1990-05-14 1991-11-28 Quadrant Holdings Cambridge Limited Stabilization of biological macromolecular substances and other organic compounds
EP0556096A1 (de) * 1992-02-13 1993-08-18 Association Pour L'essor De La Transfusion Sanguine Dans La Region Du Nord Zusammensetzung zur Stabilisierung von Blutplasma im Laufe der Pasteurisation und pasteurisierte Plasmalösung für therapeutische Verwendung
EP0556609A1 (de) * 1992-02-20 1993-08-25 EUKA BAUELEMENTE VERKAUFSGESELLSCHAFT mbH Bahnsteig
US5733873A (en) * 1992-10-02 1998-03-31 Pharmacia & Upjohn Ab Composition comprising coagulation factor VIII formulation, process for its preparation and use of a surfactant as stabilizer
WO1994017834A1 (de) * 1993-02-09 1994-08-18 Octapharma Ag Verfahren zur inaktivierung von viren, die nicht mit lipidhüllen versehen sind
WO1994026286A1 (en) * 1993-05-07 1994-11-24 Pharmacia Ab Oxygen-reduced aqueous solution of factor viii
WO1995007713A1 (en) * 1993-09-13 1995-03-23 Baxter International Inc. Activated factor viii as a therapeutic agent and method of treating factor viii deficiency

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
Andersson et al (1986), Proc. Natl. Acad. Sci. USA , vol. 83, pp. 2979 2983. *
Andersson et al (1986), Proc. Natl. Acad. Sci. USA, vol. 83, pp. 2979-2983.
Factor VIII Coagulations Sanguinis Humani Cryodesiccatus (1994) , pp. 275 1 to 275 4. *
Factor VIII Coagulations Sanguinis Humani Cryodesiccatus(1994) , pp. 275-1 to 275-4.
Goulian et al (1966), Nature , vol. 211, No. 5044, pp. 74 75. *
Goulian et al (1966), Nature, vol. 211, No. 5044, pp. 74-75.
Schwinn et al (1989), Arzneim. Forsch./Drug Res. , 39(II), No. 10, pp. 1302 1305. *
Schwinn et al (1989), Arzneim.-Forsch./Drug Res., 39(II), No. 10, pp. 1302-1305.
Wan et al (1974), Journal of Pharmaceutical Sciences , vol. 63, No. 1, pp. 136 137. *
Wan et al (1974), Journal of Pharmaceutical Sciences, vol. 63, No. 1, pp. 136-137.
Wang et al., Journal of Parenteral Science and Technology , Technical Report No. 10, 1988 Supplement, vol. 42, No. 2S. *
Wang et al., Journal of Parenteral Science and Technology, Technical Report No. 10, 1988 Supplement, vol. 42, No. 2S.

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8058226B2 (en) 1999-02-22 2011-11-15 Baxter International Inc. Albumin-free factor VIII formulations
US20040116345A1 (en) * 1999-02-22 2004-06-17 Marc Besman Novel albumin-free factor VIII formulations
US9669076B2 (en) 1999-02-22 2017-06-06 Baxalta Incorporated Albumin-free factor VIII formulations
US9352027B2 (en) 1999-02-22 2016-05-31 Baxalta Incorporated Albumin-free factor VIII formulations
US8765665B2 (en) 1999-02-22 2014-07-01 Baxter International Inc. Albumin-free factor VIII formulations
US7087723B2 (en) 1999-02-22 2006-08-08 Baxter International Inc. Albumin-free factor VIII formulations
US20060205661A1 (en) * 1999-02-22 2006-09-14 Baxter International, Inc. Novel albumin-free factor VIII formulations
US8372800B2 (en) 1999-02-22 2013-02-12 Baxter International Inc. Albumin-free factor VIII formulations
US7247707B2 (en) 1999-02-22 2007-07-24 Baxter International Inc. Albumin-free factor VIII formulations
US6586573B1 (en) * 1999-02-22 2003-07-01 Baxter International Inc. Albumin-free Factor VIII formulations
US20060159656A1 (en) * 1999-07-15 2006-07-20 American Home Products Corp. Formulations for IL-11
US20080069245A1 (en) * 2001-11-29 2008-03-20 Matsushita Electric Industrial Co., Ltd. Coding distortion removal method, video encoding method, video decoding method, and apparatus and program for the same
US20040127537A1 (en) * 2002-06-26 2004-07-01 Gokarn Yatin R. Stable liquid parenteral parecoxib formulation
ES2229931B1 (es) * 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
ES2229931A1 (es) * 2003-10-03 2005-04-16 Probitas Pharma, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
US20070105782A1 (en) * 2005-10-07 2007-05-10 Board Of Trustees Of Southern Illinois University Protectant Combinations for Reducing Toxicities
US20100316625A1 (en) * 2007-12-21 2010-12-16 Inspiration Biopharmaceuticals, Inc. Stabilized factor ix formulations containing trehalose
US20100168018A1 (en) * 2008-11-07 2010-07-01 Baxter International Inc. Factor viii formulations
US10512674B2 (en) 2008-11-07 2019-12-24 Baxalta Incorporated Factor VIII formulations
US11020459B2 (en) 2008-11-07 2021-06-01 Baxalta Incorporated Factor VIII formulations
AU2010291009B2 (en) * 2009-09-04 2013-09-26 Arecor Limited Stable formulation of Factor VIII

Also Published As

Publication number Publication date
AU709642B2 (en) 1999-09-02
EP0819010A1 (de) 1998-01-21
JP3953102B2 (ja) 2007-08-08
PT819010E (pt) 2004-01-30
DK0819010T3 (da) 2004-02-09
CA2216098C (en) 2011-08-23
NZ305028A (en) 1998-08-26
CA2216098A1 (en) 1996-10-03
WO1996030041A1 (en) 1996-10-03
JPH11502833A (ja) 1999-03-09
EP0819010B1 (de) 2003-10-08
ATE251467T1 (de) 2003-10-15
DE69630291D1 (de) 2003-11-13
ES2208736T3 (es) 2004-06-16
BR9607922A (pt) 1998-06-09
AU5293496A (en) 1996-10-16
DE69630291T2 (de) 2004-05-06
SE9501189D0 (sv) 1995-03-31

Similar Documents

Publication Publication Date Title
US5919908A (en) Protein formulation comprising coagulation factor VIII or factor IX in an aqueous solution
EP0700299B1 (de) Sauerstoff reduzierte wässerige faktor viii-enthaltene lösung
KR100303872B1 (ko) 응고인자ⅷ제형을포함하는조성물,이것의제조방법및안정화제로서의계면활성제의사용방법
EP0410207B1 (de) Stabilisierung von hochgereinigten Proteinen
AU677797C (en) Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
PL175177B1 (pl) Kompozycja farmaceutyczna zawierająca rekombinantowy czynnik krzepnięcia VIII I54) oraz sposób wytwarzania kompozycji farmaceutycznej zawierającej rekombinantowy czynnik krzepnięcia VIll

Legal Events

Date Code Title Description
AS Assignment

Owner name: PHARMACIA & UPJOHN AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:OSTERBERG, THOMAS;FATOUROS, ANGELICA;REEL/FRAME:009024/0021

Effective date: 19970905

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
AS Assignment

Owner name: BIOVITRUM AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PHARMACIA AB;REEL/FRAME:012822/0498

Effective date: 20011120

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12